Concurrent Tracks | November 2 - 3

- Fourth Annual HDAC Inhibitors
- Fifth Annual GPCR-Based Drug Discovery
- Fifth Annual Ion Channels as Therapeutic Targets
- Inaugural Targeting the PI3K Pathway

Concurrent Tracks | November 3 - 4

- Eighth Annual RNAi for Functional Screens
- Fourth Annual The Challenge of Developing Kinase Inhibitors
- Third Annual Diabetes Drug Discovery
- Inaugural New Ways to Tackle COPD and Other Chronic Pulmonary Diseases

EVENT FEATURES

- 600+ Participants
- Keynote Speakers
- Breakout Discussion Groups
- 30 Exhibiting Companies
- Dedicated Poster Viewing Hours
- 7 Short Courses (Nov. 1 + 3) (See page 3 for details)
### Conference-at-a-Glance

**MONDAY, NOVEMBER 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am–12:00 pm</td>
<td>Registration</td>
</tr>
<tr>
<td>12:00 pm–3:00 pm</td>
<td>CONCURRENT Courses 1 and 4 (see page 3)</td>
</tr>
<tr>
<td>3:00 pm–3:30 pm</td>
<td>Registration</td>
</tr>
<tr>
<td>3:30 pm–6:30 pm</td>
<td>CONCURRENT Courses 2 and 3 and 4 (see page 3)</td>
</tr>
<tr>
<td>4:30 pm–6:30 pm</td>
<td>Main Conference Early Registration</td>
</tr>
</tbody>
</table>

**TUESDAY, NOVEMBER 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am–8:30 am</td>
<td>Registration and Morning Coffee</td>
</tr>
<tr>
<td>8:30 am–10:10 am</td>
<td>CONCURRENT TRACKS 1/2/3/4</td>
</tr>
<tr>
<td>10:10 am–10:40 am</td>
<td>Grand Opening Coffee Break in the Exhibit Hall</td>
</tr>
<tr>
<td>10:40 am–12:40 pm</td>
<td>CONCURRENT TRACKS 1/2/3/4</td>
</tr>
<tr>
<td>12:40 pm–2:20 pm</td>
<td>Luncheon Presentations or Lunch on Your Own</td>
</tr>
<tr>
<td>2:20 pm–3:25 pm</td>
<td>CONCURRENT TRACKS 1/2/3/4</td>
</tr>
<tr>
<td>3:25 pm–4:05 pm</td>
<td>Networking Refreshment Break in the Exhibit Hall</td>
</tr>
<tr>
<td>4:05 pm–5:05 pm</td>
<td>CONCURRENT TRACKS 1/2/3/4</td>
</tr>
<tr>
<td>5:05 pm–6:10 pm</td>
<td>Breakout Discussion Sessions</td>
</tr>
<tr>
<td>6:15 pm–7:15 pm</td>
<td>Happy Hour in the Exhibit Hall</td>
</tr>
</tbody>
</table>

**WEDNESDAY, NOVEMBER 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am–8:00 am</td>
<td>Registration and Morning Coffee</td>
</tr>
<tr>
<td>8:00 am–9:40 am</td>
<td>CONCURRENT TRACKS 1/2/3/4</td>
</tr>
<tr>
<td>9:40 am–10:40 am</td>
<td>Networking Coffee Break in the Exhibit Hall</td>
</tr>
<tr>
<td>10:40 am–12:10 pm</td>
<td>CONCURRENT TRACKS 1/2/3/4</td>
</tr>
<tr>
<td>12:10 pm</td>
<td>Close of Tracks 1/2/3/4</td>
</tr>
<tr>
<td>12:30 pm–1:30 pm</td>
<td>Registration</td>
</tr>
<tr>
<td>1:30 pm–3:10 pm</td>
<td>CONCURRENT TRACKS 5/6/7/8</td>
</tr>
<tr>
<td>3:10 pm–3:45 pm</td>
<td>Networking Refreshment Break in the Exhibit Hall</td>
</tr>
<tr>
<td>3:45 pm–5:45 pm</td>
<td>CONCURRENT TRACKS 5/6/7/8</td>
</tr>
<tr>
<td>6:00 pm–9:00 pm</td>
<td>Dinner Short Courses (see page 3)</td>
</tr>
</tbody>
</table>

**THURSDAY, NOVEMBER 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am–8:30 am</td>
<td>Continental Breakfast Breakout Discussion Sessions</td>
</tr>
<tr>
<td>8:35 am–10:10 am</td>
<td>CONCURRENT TRACKS 5/6/7/8</td>
</tr>
<tr>
<td>10:10 am–10:55 am</td>
<td>Networking Coffee Break in the Exhibit Hall</td>
</tr>
<tr>
<td>10:55 am–12:40 pm</td>
<td>CONCURRENT TRACKS 5/6/7/8</td>
</tr>
<tr>
<td>12:40 pm–1:55 pm</td>
<td>Luncheon Presentations or Lunch on Your Own</td>
</tr>
<tr>
<td>1:55 pm–3:00 pm</td>
<td>CONCURRENT TRACKS 5/6/7/8</td>
</tr>
<tr>
<td>3:00 pm–3:40 pm</td>
<td>Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)</td>
</tr>
<tr>
<td>3:40 pm–5:10 pm</td>
<td>CONCURRENT TRACKS 5/6/7/8</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>Close of Discovery on Target</td>
</tr>
</tbody>
</table>

### Hotel & Travel Information

**CONFERENCE VENUE:**

World Trade Center
200 Seaport Blvd.
Boston, MA 02210

**CONFERENCE HOTEL:**

Seaport Hotel
One Seaport Lane
Boston, MA 02210

**Discounted Room Rate:** $235 s/d

**Discounted Cut-off Date:** September 24, 2010

Please visit our website to make your reservations online or call the hotel directly to reserve your sleeping accommodations. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

**Flight Discounts:**

To receive a 5% or greater discount on all American Airline flights please use one of the following methods:

- Call 1-800-433-1790 use Conference code A48H0AP
- Go online www.aa.com enter Conference code A48H0AP in promotion discount box
- Contact Wendy Levine, Great International Travel 1-800-336-5248 ext. 137

**Car Rental Discounts:**

Special discount rentals have been established with Hertz for this conference. Please use one of the following methods:

- Call HERTZ, 800-654-3131 use our Hertz Convention Number (CV): 04KL0001
- Go online www.hertz.com use our Hertz Convention Number (CV): 04KL0001

### Sponsorship Opportunities

Sponsorship packages give you prime access to hard to reach end-users. Speak directly to prospective clients and make an impact for your company!

**Agenda Presentations**

Speak to a captive audience about your latest product or service. This sponsorship includes a 15-minute podium presentation within the scientific agenda as well as exhibit space, onsite branding and access to cooperative marketing efforts by CHI.

**Breakfast & Luncheon Presentations**

These presentations include a 30-minute podium presentation within the scientific agenda as well as exhibit space.

**Invitation-Only VIP Dinner**

Sponsor will hand pick its top prospects and invite them to a night of networking at a top local venue. Enjoy a night of discussion and collaboration in a casual atmosphere. CHI will work closely with you to develop an invitation format and invite list.

**Focus Groups**

CHI will gladly provide you the opportunity of running a focus group on-site at Discovery On Target. This exclusive gathering can be useful to conduct market research, gather feedback on a new product idea and gather marketing intelligence from industry experts on a specific topic.

**User Group Meetings**

Co-locate your user group meeting with Discovery On Target. CHI will help market the event, manage logistical operations, develop the agenda, and more. CHI can handle the entirety of the meeting, or aspects of your choosing.

**For more information please contact:**

Jon Stroup, Manager, Business Development
781-972-5483
jstrup@healthtech.com

**Hotel Information**

[DiscoverOnTarget.com]  
Email: reg@healthtech.com  
Phone: 781-972-5400  
Fax: 781-972-5425
**Conference Short Courses**

**NOVEMBER 1, 2010**

Course 1  12:00 pm – 3:00 pm  
**Allosteric Modulators of GPCRs**  
Topics to be Covered  
- Introduction to theory, types and kinetics of allosteric modulators  
- Screening and assays for small molecule allosteric modulators of GPCRs  
- Examples of non-small molecule allosteric modulators of GPCRs  
- Case study of discovery and development of a GPCR allosteric modulator with a focus on optimization challenges  
- Q&A panel session with the instructors  

Course Instructors:  
Scott Kuduk, Ph.D., Senior Research Fellow, Medicinal Chemistry, Merck & Co.  
Shaun R. Stauffer, Ph.D., Research Assistant Professor of Pharmacology, Director of Medicinal Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center  
Annette Gilchrist, Ph.D., Assistant Professor, Midwestern University, Chicago College of Pharmacy  
Frederick Jones, M.D., President and Chief Executive Officer, Anchor Therapeutics (panelist only)  

Lunch provided, courtesy of Anchor Therapeutics

Course 2  3:30 pm – 6:30 pm  
**Structure-Based Design of Ion Channel – Linked Receptors**  
Topics to be Covered  
- High – Throughput screening of channel inhibitors  
- Automated patch clamp for screening  
- NMR for structure – based design  
- Current technologies  

Designing a QPatch Assay; Help for Beginners  
Dayne Okuhara, Ph.D., Scientist, Synta Pharmaceuticals, Corp.  

Additional Instructors to be Announced

**NOVEMBER 3, 2010**

Course 5  8:00 am – 12:00 pm  
**Best Practices for Setting Up Effective RNAi Screens**  
The course is designed to provide in-depth information on how to go about setting up RNAi screening experiments and how to design assays for getting optimal results. The challenges working with siRNAs and shRNAs and the delivery reagents needed to get them into the appropriate cells and tissues will be discussed. The instructors will also provide their input on best practices for the execution of experiments and interpretation of results when dealing with complex biology and informatics.  

Course Instructors:  
Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center  
Namjoo Chun, Ph.D., Senior Research Investigator, Applied Genomics, Bristol-Myers Squibb Co.  
Marc Ferrari, Ph.D., Team Leader, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health  
Serena Silver, Ph.D., RNAi Screening Projects Group Leader, Broad Institute at MIT  

Course 6  6:00 pm – 9:00 pm  
**DINNER COURSE  
In vivo Discovery and Validation Using RNAi**  
In vivo experiments with RNAi are proving to be more complex and intricate than those done in vitro. This course is designed to provide experimental and technical details involving the design and use of such RNAi-based in vivo screens. Questions surrounding the choice and use of appropriate reagents and animal models, criteria for experimental design and quality control, immunogenic and off-target effects, and other important issues will be discussed in extensive detail. The course will also go over the challenges surrounding efficient delivery of siRNA or shRNA molecules into the cell, tissue uptake and retention, success of systemic and local delivery, and instructors will offer guidance and alternatives based on their expertise and experiences. These in vivo based RNAi screens cover a diverse range of applications such as, screens for functional analysis of cellular pathways and moieties, for understanding the biology of a disease, for validation of drug targets, and many others. Scientists involved in these areas of research or those looking to learn more about how these screens are effectively designed and used are encouraged to participate.  

Course Instructors:  
Ann Conery, Ph.D., Director, C. elegans Screening Core, Department of Molecular Biology, Massachusetts General Hospital  
Siew Ho, Ph.D., Senior Principal Scientist, Applied Biotechnology, Bristol-Myers Squibb Co.  
Lizabeh Parks, Ph.D., Associate Professor of Pediatrics/Genetics, Pediatric Surgical Research Laboratory s. Massachusetts General Hospital; Director, Transgenic RNAI Project at Harvard Medical School

**8:00 pm – 8:30 pm Dinner Presentation**  
**KinaseSwitch and RNAi Technology Platforms**  
Kenneth D. Campbell, Ph.D., Associate Director, Scientific Commercial Development, Taconic  

Novel in vivo technology platforms have recently been developed and validated, which enable investigators to gain greater insights into drug and target-related disease mechanisms. TaconicArtemis’ transgenic RNAi mouse models are innovative, commercially available additions to the aforementioned technologies. Inducible/reversible RNAi technology enables gene knockdown in all tissues of the body and can be induced as well as reversed, providing an optimal surrogate for therapeutic drug action. The use of transgenic RNAi technology to validate gene function in relevant disease models will be presented.  

Course 7  6:00 pm – 9:00 pm  
**DINNER COURSE  
Assessing Cardio Safety of Diabetes Drug Candidates**  
This workshop is designed to help scientists understand and discuss their diabetes drug development work in the context of the cardio-safety guidelines issued by the FDA in 2008 and recent high-profile FDA decisions related to currently marketed diabetes drugs.  
- Historical perspective on how we’ve gotten to this point in safety assessment  
- Basics of micro- v. macrovascular complications of diabetes (DCCT and UKPDS trials)  
- Glucose control v. CV outcome: lessons from large outcome trials such as Acord/Advance/VADT  
- Discussion of the new FDA Guidance and regulatory expectations in detail  
- Lessons learned from the Avandia cardio-safety issues  
- Case studies and interactive discussion with course participants around the challenge of conducting clinical trials in reasonable amount of time and cost  

Instructors:  
G. Alexander Fleming, M.D., President and CEO, Kinexum (formerly responsible for diabetes drugs, Division of Metabolic and Endocrine Drug Products, FDA)  
Michael Trautmann, M.D., Senior Medical Fellow, Lilly Diabetes, Eli Lilly & Company

*Separate registration required.*

**CHI's Intro-Net: Networking at its Best!**  
Maximize Your Experience On-site at Discovery On Target!  

The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is available only to registered session attendees of this event. Registered conference attendees will receive more information on how to access the Intro-Net in the weeks leading up to the event!

**Stay Connected!**

Add a short course to your conference registration and save $100!
Fourth Annual
HDAC Inhibitors
Tracking Pre-Clinical and Clinical Progress in Oncology, CNS, Inflammation and More

November 2-3, 2010

TUESDAY, NOVEMBER 2

7:00 am  Conference Registration and Morning Coffee

EXPLORING EFFICACY AND SPECIFICITY OF HDAC INHIBITORS

8:30  Chairperson’s Opening Remarks
James Bradner, M.D., M.Sc., Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute

8:40  What's Next for HDAC Inhibitors - Better Combinations or Better Specificity?
Sriram Balasubramanian, Ph.D., Senior Director, Translational Research, Pharmacyclics, Inc.

9:10  Proteomic Approach to Define the Anti-Tumor Effects of an HDACi as Single Agent or in Combination Treatment
Alfredo Budillon, M.D., Ph.D., Chief, Experimental Pharmacology Unit, National Cancer Institute, G. Pascale, Italy

9:40  Augmenting the Efficacy of HDAC Inhibitors
Joy Chandra, Ph.D., Associate Professor of Pediatrics Research, Children’s Cancer Hospital, M.D. Anderson Cancer Center, University of Texas

10:10  Grand Opening Coffee Break in the Exhibit Hall

10:40  Non-Peptide Macrocyclic Histone Deacetylase Inhibitors for Targeted Cancer Treatment
Yomi Oyelere, Ph.D., Assistant Professor of Chemistry and Biochemistry, Georgia Institute of Technology

11:10  Sensitive HTS Assays to Interrogate Histone Deacetylase (HDAC) & Sirtuin Enzymes
Andrew Niles, Senior Research Scientist, Promega

11:40  New HDAC Inhibitors for Hematologic Malignancies
James Bradner, M.D., M.Sc., Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute

12:20  Using AR-42 to Better Understand the Mechanism of HDAC Inhibition
Craig Hofmeister M.D., Assistant Professor of Medicine, Multiple Myeloma Clinical Lead, The Ohio State University Comprehensive Cancer Center

12:40  Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

UNDERSTANDING THE CELLULAR EFFECTS OF HDACs

2:20  Chairperson’s Remarks
Stanley Spence, Ph.D., Executive Director, Preclinical Safety Assessment, Novartis Institutes of Biomedical Research

2:25  Inherent Epigenetic Make-Up of Cancer Cells and their Predisposition to HDACi Sensitization
France Carrier, Ph.D., Associate Professor, Radiation Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland

3:25  Networking Refreshment Break in the Exhibit Hall

4:05  KEYNOTE PRESENTATION: Function, Mechanism of Action, and Regulation of HDACs
Edward Seto, Ph.D., Chairman, Department of Molecular Oncology, H. Lee Moffitt Cancer Center

5:05  Interactive Breakout Discussion Groups

6:15 – 7:15  Happy Hour in the Exhibit Hall

WEDNESDAY, NOVEMBER 3

7:15 am  Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

PROGRESS IN PRE-CLINICAL AND CLINICAL DEVELOPMENT OF HDACs

8:00  Chairperson’s Opening Remarks
Sriram Balasubramanian, Ph.D., Senior Director, Translational Research, Pharmacyclics, Inc.

8:10  Phase II Clinical Development of resminostat, a Novel Oral Histone Deacetylase Inhibitor in Neoplastic Disease
Stefan W. Henning, Ph.D., Project Manager, Development, 4SC AG

8:40  Pre-Clinical and Clinical Development of HDACi to Reverse Hormone Resistance in Breast Cancer
Pamela Munster, M.D., Associate Professor, Department of Medicine, University of California, San Francisco

9:10  Clinical Update on panobinostat
Murielle Mueller, Assistant Director, Global Medical Affairs, Novartis

9:40  Networking Coffee Break in the Exhibit Hall

10:40  Targeting of HDAC Inhibitors to Monocytes and Macrophages: Potential in Cancer and Inflammatory Disease
Scott Cuthill, PhD, Associate Director Business Development, Chroma Therapeutics Ltd

11:10  A Dose-escalating Clinical Trial Evaluating the Combination of Suberoylanilide Hydroxamic Acid with Capcitabine Using a New Weekly Dose Regimen for Advanced Breast Cancer
Maysa Abu-Khalaf, M.B.B.S., Assistant Professor, Medical and Gynecology Oncology, Yale Comprehensive Cancer Center

11:40  Development of a Selective HDAC Inhibitor for Friedreich's Ataxia
James Rusche, Ph.D., Senior Vice President, Research & Development, Repligen Corporation

12:10 pm  Close of Conference
**Fifth Annual**

**GPCR-Based Drug Discovery**

Designing and Optimizing Therapies Targeting GPCRs

**TUESDAY, NOVEMBER 2**

7:00 am  Conference Registration and Morning Coffee

**GPCR’S IN DISEASE**

8:30  Chairperson’s Opening Remarks

8:40  Discovery of Ligands for the Hydroxy-Carboxylate Receptors GPR109a and GPR109b
Graeme Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals

9:10  Comparative evaluation of Allosteric Inhibitors for the Chemokine Receptor CCR1
Annette Glidtch, Ph.D., Assistant Professor, Midwestern University, Chicago College of Pharmacy

9:40  Drug Discovery of GPCR (SIP1 or IP)-Targeted Candidate (preliminary title)
John Gatfield, Ph.D., Senior Laboratory Head, Cardiovascular and Fibrosis Biology, Actelion Pharmaceuticals, Ltd.

10:10  Grand Opening Coffee Break in the Exhibit Hall

**PROBING SIGNALING COMPLEXITIES**

10:40  Employing Homogenous Time-Resolved FRET to Probe the Quaternary Organization of GPCRs
Graeme Milligan, Ph.D., Professor, University of Glasgow

11:10  Accelerating Lead Optimization of Drug Candidates Through Iterative Screening and Modeling
Alan H. Katz, Ph.D., Chief Scientific Officer, Hudson Robotics, Inc.

11:25  Harnessing the Benefits of GPCR Signaling Complexity with the CellKey® System
Catherine Parrish, Application Scientist, Molecular Devices, Inc.

11:40  Use of Encoded Library Technology for Discovery of Small Molecule Ligands to GPCRs
David Israel, Ph.D., Director of Cell and Molecular Technologies, Molecular Discovery Research Boston, GlaxoSmithKline

12:10  Mechanism of Allosteric Modulation by CXCR4 Peptidcins
Stephen Hunt III, Ph.D., Senior Vice President, Discovery Research, Anchor Therapeutics

12:40  Luncheon Presentation
Accelerate Your Research with OriGene’s GPCR Resource: cDNA Clones, shRNAs, and Stable Cell Lines
Xuan Liu, Ph.D., Director of Marketing, OriGene

**NEW APPROACHES TO GPCR DRUG DISCOVERY**

2:20  Chairperson’s Remarks

2:25  Case Study of GPCR-Based Drug Discovery Using High Content Screening
Lisa Smith, M.S., Scientist, In Vitro Pharmacology, Merck Research Labs

**WEDNESDAY, NOVEMBER 3**

7:15 am  Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

**GPCR STRUCTURE**

8:00  Chairperson’s Opening Remarks
Sid Topiol, Ph.D., Research Fellow, Computational Chemistry, Lundbeck Research USA, Inc

8:10  Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism
Jonathan M. Moore, Ph.D., Senior Director, Structural Biology, Vertex Pharmaceuticals Incorporated

8:40  KEYNOTE PRESENTATION: All-Atom Molecular Dynamic Simulation of an Opsin-Transducin Complex in a Membrane Bilayer
Thomas Sakmar, M.D., Professor, Molecular Biology and Biochemistry, Rockefeller University

9:40  Networking Coffee Break in the Exhibit Hall

10:40  Structural Basis for Ligand-Induced Pathway-Biased Signaling in 7TM receptors
Thue W. Schwartz, Ph.D., Professor, The Novo-Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen

11:10  Enabling Structure-Based Compound Design of GPCRs Through Biophysical Characterization
Mike Hanson, Ph.D., Associate Director Structural Biology, Receptos, Inc.

11:40  Impact of Recent X-Ray Structure Determinations on Structure-Based Drug Design for GPCRs and other CNS Targets
Sidney Topiol, Ph.D., Chief Scientific Officer, 3D-2Drug; Research Fellow, Computational Chemistry, Lundbeck Research USA, Inc

12:10 pm  Close of Conference
Fifth Annual
Ion Channels as Therapeutic Targets
Discovering and Optimizing Drug Development Candidates

TUESDAY, NOVEMBER 2

7:00 am  Conference Registration and Morning Coffee

KEYNOTE PRESENTATIONS

8:30  Chairperson’s Opening Remarks

8:40  Ion Channels: Targets of Therapy and the Subject of Safety
Gregory J. Kaczmarski, Ph.D., President, CEO, Kanalis Consulting, L.L.C.; Adjunct Professor, Physiology and Pharmacology, New Jersey Medical School; Adjunct Professor, Physiology and Biophysics, Robert Wood Johnson Medical School

9:25  Evolving Approaches to Ion Channel Drug Discovery in Big Pharma
Laszlo Kiss, Ph.D., Senior Research Fellow, Merck Research Laboratories

10:10  Grand Opening Coffee Break in the Exhibit Hall

ION CHANNEL MODULATORS

10:40  Denudosol for Cystic Fibrosis: An R&D Case Study of an Investigational GPCR Agonist that Functions as an Ion Channel Regulator
Tomas Navratil, Ph.D., Director, Pulmonary Scientific Affairs, R&D, Inspire Pharmaceuticals

11:10  The IonWorks Barracuda System, a 384-Well Automated Electrophysiology Platform for Ligand-or Voltage-Gated Ion Channels
Karen Cook, M.S., Application Scientist, Automated Electrophysiology, Molecular Devices, Inc.

11:40  Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis
Fredrick VanGoor, Ph.D., Scientist II, Vertex Pharmaceuticals

12:10 pm  Modulation of Sodium Channel Currents by Physiological Concentration of Thyroid Hormone L-Thyroxine
James Cao, Ph.D., Staff Scientist, Signal transduction, Ordway Research Institute

12:40  Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

2:20  Chairperson’s Remarks

NOVEL TARGETS

2:25  Kv1.3: A New Class of Therapeutic Target for Type 2 Diabetes
Chuan-Chu Chou, Ph.D., Research Fellow, Merck

WEDNESDAY, NOVEMBER 3

7:15 am  Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

NOVEL APPROACHES

8:10  ROMK as a Novel Diuretic Target
Jerod S. Denton, Ph.D., Assistant Professor, Anesthesiology and Pharmacology, Vanderbilt University Medical Center

8:40  Kidney Potassium Channels: Targets for Anti-Hypertensives?
Birgit T. Priest, Ph.D., Senior Research Fellow, Merck Research Laboratories

9:10  Regulation of Epithelial Sodium Channels by External Cues
Thomas Kleyman, M.D., Chief, Renal-Electrolyte Division, Professor, Medicine, Cell Biology and Physiology, and Pharmacology, University of Pittsburgh

9:40  Networking Coffee Break in the Exhibit Hall

SAFETY RISKS

10:40  Preclinical Evaluation of Safety risks for Cardiac Ion Channels: hERG and Beyond
Gul Erdemli, M.D., Ph.D., Head of Ion Channel Group, Novartis

11:10  Improving Lead Generation

11:40  Expert Panel Discussion

12:10 pm  Close of Conference

Email: reg@healthtech.com  Phone: 781-972-5400  Fax: 781-972-5425
Inaugural November 2-3, 2010

Targeting the PI3K Pathway
Inhibiting Signaling of PI3K, Akt and mTOR

TUESDAY, NOVEMBER 2

7:00 am  Conference Registration and Morning Coffee

IDENTIFYING AND DEVELOPING NOVEL INHIBITORS

8:30  Chairperson’s Opening Remarks
Kevin Liu, Ph.D., Senior Principle Scientist, Pfizer, Inc.

8:40  Design and Development of Novel, Isoform-Selective PI3K Inhibitors for the Treatment of Immune-Inflammatory Diseases and Cancer
Stephen J. Shuttleworth, Ph.D., FRSC CChem, CSO, Karus Therapeutics, Ltd.

9:10  From PI3K/mTOR Dual Inhibitors to PI3K and mTOR Selective Inhibitors
Kevin Liu, Ph.D., Senior Principle Scientist, Pfizer, Inc.

9:40  Genome-Wide RNAi Screening Identifies New Components of the mTOR Signaling Pathway in Pancreatic Cancer Cells
Angela Papageorgiou, Ph.D., Research Fellow, Massachusetts General Hospital and Harvard Medical School

10:10  Grand Opening Coffee Break in the Exhibit Hall

10:40  The Effect of Mutual Suppression of the PI3K/Akt/mTOR Pathway by Combining Rapamycin and Perifosine
Noopur Raje, M.D., M.B., Assistant Professor, Medicine, Massachusetts General Hospital, Harvard Medical School

11:10  PI3K (PIK3CA) Mutation Analysis: Challenges in Companion Diagnostic Development
Dr. David M. Jackson, Ph.D., Senior Director, Pharma Business Development, QIAGEN

11:25  Sponsored Presentation (Opportunity Available)

11:40  Talk Title to be Announced
Laurent Salphati, Pharm.D., Ph.D., Scientist, Drug Metabolism and Pharmacokinetics, Genentech

12:10 pm  EXPERT PANEL DISCUSSION: Targeting the PI3K Pathway - Which are Promising Approaches?

12:40  Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

FROM PRE-CLINICAL TO CLINICAL SUCCESS

2:20  Chairperson’s Remarks

2:25  Development of the Clinical Stage Dual mTOR-PI3K Inhibitor SF1126
Joseph R. Garlich, Ph.D., CSO, Semafore Pharmaceuticals

2:55  Pre-Clinical Characterization of Novel mTORC1 and mTORC2 Inhibitors
Shripad Bhagwat, Ph.D., Research Investigator, Biochemical and Cellular Pharmacology, OSI Pharmaceuticals, Inc.

3:25  Networking Refreshment Break in the Exhibit Hall

4:05  Palomid 529, a dual TORC1/TORC2 Allosteric Inhibitor of the PI3K/Akt/mTOR Pathway
David Sheirin, Ph.D., President and CEO, Paloma Pharmaceuticals, Inc.

4:35  Discovery of Novel Multiplex PI3 Kinase Inhibitors for the Treatment of Cancer
Dapeng Qian, M.D., Ph.D., Senior Director, Drug Discovery, Progenics Pharmaceuticals, Inc.

5:05  Interactive Breakout Discussion Groups

6:15 – 7:15  Happy Hour in the Exhibit Hall

WEDNESDAY, NOVEMBER 3

7:15 am  Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

EXPLORING DIFFERENT PATHWAY OPTIONS

8:00  Chairperson’s Opening Remarks

8:10  Feedback from Roundtable Moderators

8:40  PI3Kalpha Isoform Selective Inhibitors For targeting Human Cancer Genetics
Michael Martin, Ph.D., Vice President, Preclinical Development, Intellikine, Inc.

9:10  PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Ensar Halilovic, Ph.D., Novartis Institutes for BioMedical Research, Inc.

9:40  Networking Coffee Break in the Exhibit Hall

10:40  Talk Title to be Announced
Juswin der Singh, Ph.D., CSO, Avila Therapeutics

11:10  Allosteric Akt Inhibitors
Hans E. Huber, Ph.D., Senior Investigator, Cancer Research, Merck and Co., Inc. (tentative)

11:40  Identification of PKI-179 as a Potent and Orally EFFICACIOUS PI3 Kinase Inhibitor
Zecheng Chen, Ph.D., Principal Research Scientist, Pfizer, Inc.

12:10 pm  Close of Conference

Reasons You Should Present Your Research Poster at Discovery on Target 2010:

• Your poster will be exposed to over 600 delegates to leaders from top pharmaceutical, biotech, academic and government institutes
• Receive $50 off your registration fee
• Your poster abstract will be included in our conference materials

Please register for the meeting and we will send you abstract submissions instructions via email. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, accepted and registration paid in full by September 22, 2010.
Eighth Annual

RNAi for Functional Screens

Effectively Utilizing RNAi as a Tool for Screening Cellular Pathways and Drug Targets

November 3-4, 2010

WEDNESDAY, NOVEMBER 3

12:30 - 1:30 pm Conference Registration

SEEKING NOVEL DRUG TARGETS

1:30 Chairperson’s Remarks
Albert B. Seymour, Ph.D., Director of Biological Profiling, Target Generation Unit, Biotherapeutics and Bioinnovation Center, Pfizer, Inc.

1:40 A Physiologically-Relevant Assay System for Amyloid Precursor Protein Target Identification
Shane Marine, Ph.D., Senior Research Biochemist, Merck Research Laboratories, Department of Automated Biotechnology

2:10 An Image-Based siRNA Screen for Kinase Genes That are Important for Cancer Cells to Adapt to Hypoxia
Steven Harney, Ph.D., Associate Fellow, Applied Quantitative Geno-therapeutics, Pfizer BioTherapeutics and Bioinnovation Center, Pfizer Inc.

2:40 RNAi Screen With a High-Throughput qRT-PCR Assay Readout for Novel Target Identification
Namjin Chung, Ph.D., Senior Research Investigator, Applied Genomics, Bristol Myers Squibb Co.

3:10 Networking Refreshment Break in the Exhibit Hall

3:45 Synthetic Lethal siRNA Screens Using Pre-Clinical Compounds
Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research

4:15 Strategies for Improving RNAi Screening Success: Using a Ubiquitin-EGFP Assay to Identify Druggable Genes Required for Proteasome Function
James Goldmeyer, Ph.D., Field Application Scientist, Thermo Scientific

4:45 Translating Human Genetic Discoveries to Novel Targets and Therapeutics
Albert B. Seymour, Ph.D., Director of Biological Profiling, Target Generation Unit, Biotherapeutics and Bioinnovation Center, Pfizer, Inc.

5:15 PANEL DISCUSSION: The Current Fate of Drug Targets Being Uncovered by RNAi Screens
Moderator: Albert B. Seymour, Ph.D., Director of Biological Profiling, Target Generation Unit, Biotherapeutics and Bioinnovation Center, Pfizer, Inc.

5:45 End of Day

6:00 pm – 9:00 pm Conference Short Course*

DINNER COURSE

In vivo Discovery and Validation Using RNAi

See details on page 3. * Separate registration required.

THURSDAY, NOVEMBER 4

7:30 am Interactive Breakfast Breakout Discussion Groups

DIVERSIFYING FUNCTIONAL GENOMIC SCREENS

8:35 Chairperson’s Opening Remarks
Marc Ferrer, Ph.D., Team Leader, NIH Chemical Genomics Center /National Human Genome Research Institute , National Institutes of Health

8:40 A Comprehensive Strategy From RNAi Screening, Through Validation, Genomic Analysis, Comparative Biology to Biological Target
Alex Bishop, Ph.D., Assistant Professor, Cellular and Structural Biology, University of Texas Health Science Center, San Antonio

9:10 DNAi, mRNA Biogenesis and Genome-Wide Drug Modifier Screens
Hakim Djeballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center

9:40 Functional Genomic Strategies for Defining Host-Pathogen Interactions
Abraham Brass, M.D., Ph.D., Investigator, Ragon Institute of Massachusetts General Hospital, Harvard Medical School

10:10 Networking Coffee Break in the Exhibit Hall

10:55 RNAi Screening in Cancer Cell Lines: Synthetic Lethals and Oncogene Modulators
Joanna Holbrook, Ph.D., Protein Dynamics DPU, Cancer Research, Oncology R&D, GlaxoSmithKline Plc.

11:25 Patent Considerations and Trends in RNAi
Steven L. Highlander, Ph.D., Partner, Intellectual Property, Fulbright & Jaworski LLP

James Coburn, President/CEO, Harbor Consulting

12:25 RNAi Screening in the Human Muscle Line, RD1: A Functional Genomics Screen to Enhance Insulin Signaling
James Fischer, Ph.D., Senior Scientist, Compound Safety Prediction, WW Medicinal Chemistry, Pfizer, Inc.

12:55 Luncheon Presentation: Introducing “PhenoTaq”™ – An Efficient, Comprehensive Platform for Genetic Target Validation
Kenneth D. Campbell, Ph.D., Associate Director, Scientific Commercial Development, Taconic

EXPLORING HIGH-THROUGHPUT, HIGH-CONTENT RNAI SCREENS

1:55 Chairperson’s Remarks
Shane Marine, Ph.D., Senior Research Biochemist, Merck Research Laboratories, Department of Automated Biotechnology

2:00 KEYNOTE PRESENTATION: Applying High-Throughput RNAi to Empower Systems Biology
Spyro Moussas, Ph.D., Vice President, Office of Innovation; Director, Center of BioIntelligence, Translational Genomics Research Institute

3:00 Networking Ice Cream Refreshment Break in the Exhibit Hall

3:40 Quantitative Multi-Parametric Image Analysis to Determine Off-Target Effects
Marc Bickle, Ph.D., Head HT-Technology Development Studio, Max Planck Institute of Molecular Cell Biology and Genetics

4:10 High-Content Assay Development in Macrophages: Applications for Host-Pathogen Screening
Iain Fraser, Ph.D., Investigator, Program in Systems Immunology and Infectious Disease Modeling (PSIIM) National Institute of Allergy and Infectious Diseases National Institutes of Health

4:40 Forcing Glioblastoma Tumor Initiating Cells to Differentiate: An High Throughput, High Content Imaging Screen to Target Transcription Factors and GTPases
Milan Chheda, M.D., Post-doctoral Fellow, Dana Farber Cancer Institute, Broad Institute, and Memorial Sloan-Kettering Cancer Center

5:10 Close of Conference

Sponsored by

Thermo Scientific

DiscoveryOnTarget.com

Email: reg@healthtech.com Phone: 781-972-5400 Fax: 781-972-5425
The Challenge of Developing Kinase Inhibitors
Targeting Selectivity, Specificity, and Novel Therapeutic Areas

WEDNESDAY, NOVEMBER 3

12:30 - 1:30 pm Conference Registration

KINASE INHIBITOR CHEMISTRY

1:30 Chairperson’s Remarks

1:40 Scaffold-Based Inhibitor Design Strategies Targeting Type II and Allosteric Sites: Future Beyond the Kinase Domain
Hariprasad, Vakayalapati, M. Pharm., Ph.D., Chief Scientist, Medicinal Chemistry, Center for Investigational Therapeutics, Huntsman Cancer Institute

2:10 Fragments and Drug Discovery for Kinase Targets
Roderick E. Hubbard, Ph.D., Senior Fellow, Research, Vernalis, Ltd.

2:40 Scaffold Hopping as a Method to Diversify and Generate New Leads for p38
Kristoffer Moffett, Ph.D., Senior Scientist, Chemistry, Ansaris, a division of Locus Pharmaceuticals, Inc.

3:10 Networking Refreshment Break in the Exhibit Hall

3:45 Fragment Replacement for Lead Generation
Roger Armen, Ph.D., Scientist, Department of Chemistry, University of Michigan

4:15 Sponsored Presentation (Opportunity Available)

4:45 Talk Title to be Announced
Yogesh Sabnis, Ph.D., Computational Chemist, Pfizer Ltd.

5:15 Expert Panel Discussion: How much of a Challenge is the Selectivity of Kinase Inhibitors?

5:45 End of Day

THURSDAY, NOVEMBER 4

7:30 am Interactive Breakfast Breakout Discussion Groups

OPTIMIZING LEADS

8:35 Chairperson’s Opening Remarks

8:40 Feedback from Roundtable Breakout Discussions

9:10 Hit to Lead Optimization of B-Raf Kinase Inhibitors
Ariamala Gopalsamy, Ph.D., Principal Scientist III, Pfizer, Inc.

9:40 Talk Title to be Announced
Jan Hoflack, Ph.D., Vice President Discovery, Oncodesign

10:10 Networking Coffee Break in the Exhibit Hall

SAFETY CONSIDERATIONS

10:55 Selected Poster Presentation

11:25 Small Molecule Kinase Inhibitor Promiscuity: Translating Kinase Selectivity Into Early Safety Guidance
Andrew Olaharski, Ph.D., DABT, Head of Early Safety Representatives, Hoffmann-La Roche; Nutley, NJ

11:55 Expert Panel Discussion: Tackling the Fine Line between Safety and Toxicity

12:25 pm Luncheon Presentation (Opportunity Available)

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

NOVEL TARGETS AND THERAPEUTIC AREAS

1:55 Chairperson’s Remarks

2:00 Discovery of Novel, Potent Non-ATP Competitive MK2 Inhibitors
Dong Xiao, Ph.D., Principal Scientist, Chemical Research Department, Merck Research Laboratories

2:30 Development of a Novel Kinase Inhibitors for Treatment of Neuroinflammation
Anumantha Kanthasamy, Ph. D., Distinguished Professor and W. E. Lloyd Chair, Biomedical Sciences, Iowa State University

3:00 Networking Ice Cream Refreshment Break in the Exhibit Hall

3:40 ARQ 197, A Novel and Selective Inhibitor of the Human c-Met receptor Tyrosine Kinase with Antitumor Activity
Dennis S. France, Ph.D., Vice-President, Molecular Oncology, ArQule, Inc.

4:10 Developing Novel Kinase Inhibitors for Neurodegenerative Diseases
Min Liu, Ph.D., Instructor, Neurology, Brigham and Women’s Hospital

4:40 Expert Panel Discussion: The Challenge of Finding New Therapeutic Areas - Are there Still Bigger Fish to Catch?

5:10 Close of Conference
## WEDNESDAY, NOVEMBER 3

**12:30 - 1:30 pm**  Conference Registration

**DIABETES DRUG DEVELOPMENT CHALLENGES**

**1:30 pm**  Chairperson’s Remarks
Rebecca Taub, M.D., Senior Vice President, R&D, VIA Pharmaceuticals

**1:40 pm**  KEYNOTE PRESENTATION: Future Treatment of Diabetes: Integrating Perspectives From Bench, Bedside, and Beyond
Jorge Plutzky, M.D., Director, The Vascular Disease Prevention Program, Cardiovascular Division, Brigham and Women’s Hospital; Associate Professor, Harvard Medical School

**2:25 pm**  OPENING PANEL: CLINICAL DEVELOPMENT CONSIDERATIONS
Moderator: Rebecca Taub, M.D., Senior VP R&D, VIA Pharmaceuticals
- What will the ideal future regimen look like?
- Combination therapies?
- Different regimens for different patient populations?
- How much and at what point in development is some CV risk acceptable?
Panelist: Michael Trautmann, M.D., Senior Medical Fellow, Lilly Diabetes, Eli Lilly & Company

**3:10 pm**  Networking Refreshment Break in the Exhibit Hall

**TARGETING G PROTEIN COUPLED RECEPTORS TO MODULATE INSULIN LEVELS**

**3:45 pm**  Glucagon Receptor Antagonists (tentative title) Michael Miller, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Merck

**4:15 pm**  Economic and Scientific Considerations for High Throughput and Selective Drug Screening in Diabetes - The Value of Using Human Tissue
Kenneth L. Brayman, M.D., Ph.D., FACS, Principal Scientific Advisor, Betapro, LLC

**4:45 pm**  GPR39, A Novel Target for Type-2 Diabetes and Obesity
Birgit Holst, Ph.D., Associate Professor, University of Copenhagen

**5:15 pm**  Targeting Entero-Endocrine 7TM Chemo-Sensors for Metabolic Diseases
Thue W. Schwartz, Ph.D., Professor, The Novo-Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen

**5:45 pm**  End of Day

### November 3 Dinner Short Course

**Assessing Cardio Safety of Diabetes Drug Candidates**

See details on page 3. *Separate registration required.

## THURSDAY, NOVEMBER 4

**7:30 am**  Interactive Breakfast Breakout Discussion Groups

**NEW DIABETES PATHWAYS AND DRUG CANDIDATES**

**8:35 am**  Chairperson’s Opening Remarks
Andrew G. Swick, Ph.D., Nutrition Research Institute, Department of Nutrition, University of North Carolina at Chapel Hill

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:40</td>
<td>11beta-HSD1 Inhibition in Type 2 Diabetes</td>
</tr>
<tr>
<td></td>
<td>Reid Huber, Ph.D., Executive Director, Clinical Development, Incyte Corp.</td>
</tr>
<tr>
<td>9:10</td>
<td>Separating Mitogenic and Metabolic Activities of FGF19</td>
</tr>
<tr>
<td></td>
<td>Yang Li, Ph.D., Scientific Director, Metabolic Disorders, Amgen, Inc.</td>
</tr>
<tr>
<td>9:40</td>
<td>Use of a Small Molecule Inhibitor of Macrophage Migration Inhibitory Factor is Therapeutic in Treatment of Non-Insulin-Dependent Diabetes Mellitus</td>
</tr>
<tr>
<td></td>
<td>Thais Sielecki, Ph.D., VP, Preclinical Development, R&amp;D, Cytokine</td>
</tr>
<tr>
<td>10:10</td>
<td>Networking Coffee Break in the Exhibit Hall</td>
</tr>
<tr>
<td>10:55</td>
<td>Systems Approaches to Modeling Diabetes within Pfizer</td>
</tr>
<tr>
<td></td>
<td>Avijit Ghosh, Ph.D.; Senior Principal Scientist; Department of Pharmacokinetics, Dynamics and Metabolism; Pfizer Global Research and Development</td>
</tr>
<tr>
<td>11:15</td>
<td>Update on a New Diabetes Target (tentative title)</td>
</tr>
<tr>
<td></td>
<td>Andrée R. Olivier, Ph.D., Biomarker Experimental Medicine Leader, Metabolic and Vascular Diseases, Roche</td>
</tr>
<tr>
<td>11:55</td>
<td>PR119 Agonists for the Treatment of Diabetes</td>
</tr>
<tr>
<td></td>
<td>Gaerne Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>12:25 pm</td>
<td>Sponsored Presentation (Opportunity Available)</td>
</tr>
<tr>
<td>12:40</td>
<td>Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own</td>
</tr>
</tbody>
</table>

### Turfing the Pancreas and Obesity (continued)

**3:00 pm**  Networking Ice Cream Refreshment Break in the Exhibit Hall

**3:40 pm**  Contrave: Weight Loss and Improvements in A1C in Patients with Type 2 Diabetes
Holly Maier, Ph.D., Medical Affairs, Orexigen Therapeutics, Inc.

**4:10 pm**  Enteropeptidase: A Gene Associated to a Lean Human Phenotype as a Novel Target for the Treatment Obesity and Type II Diabetes
Itzik Harosh, Ph.D., Founder and CEO, Obetherapy

**4:40 pm**  Preclinical Models for Quantifying Pancreatic Beta Cell Regulation
Alokesh Duttaroy, Ph.D., Investigator, Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Inc.

**5:10 pm**  Close of Conference
Inaugural

New Ways to Tackle COPD and Other Chronic Pulmonary Diseases
Probing Novel Drug Targets, Disease Models, Biomarkers and Treatment Options

WEDNESDAY, NOVEMBER 3

12:20 - 1:30 pm  Conference Registration

NEW PATHWAYS AND MOLECULAR TARGETS FOR TREATING COPD

1:30  Chairperson’s Remarks

1:40  KEYNOTE PRESENTATION: Overcoming Steroid Insensitivity in COPD
Ian Adcock, Ph.D., Professor, Respiratory Cell & Molecular Biology, Airways Disease Section, National Heart and Lung Institute and Faculty of Medicine, Imperial College, London

2:40  Autophagy in COPD
Augustine Choi, M.D., Department of Medicine, Harvard Medical School and Chief, Pulmonary and Critical Care Medicine, Brigham And Women’s Hospital

3:10  Networking Refreshment Break in the Exhibit Hall

3:45  Presentation to be Announced

4:15  Sponsored Presentation (Opportunity Available)

4:45  A Decoy CXCL8 Shows Potent Anti-Inflammatory Activity in Murine Lung Inflammation Models of COPD
Andreas J. Kungl, Ph.D., CSO, ProtAffin Biotechnologie AG

5:15  PANEL DISCUSSION: What Are the Biggest Challenges in COPD Over the Next Decade?
Moderator: Augustine Choi, M.D., Department of Medicine, Harvard Medical School and Chief, Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital

5:45  End of Day

THURSDAY, NOVEMBER 4

7:30 am  Interactive Breakfast Breakout Discussion Groups

INSIGHTS INTO PATHOGENESIS OF COPD

8:35  Chairperson’s Opening Remarks

8:40  NK Cell Function in COPD: Functions in Disease Progression and Viral Exacerbations
Michael Borchers, Ph.D., Assistant Professor, Department of Environmental Health, University of Cincinnati

9:10  Role of RTP801 and Stress-Sensing in Cigarette Smoke-Induced Lung Injury
Rubin M. Tuder, M.D., Director, Program in Translational Lung Research, Division of Pulmonary and Critical Care Medicine, University of Colorado Denver, School of Medicine

9:40  Therapeutic Potential of JBT-1 in Lung Injury and COPD
Jeanine D’Armiento, M.D., Ph.D., Associate Professor, Department of Medicine, Columbia University

10:10  Networking Coffee Break in the Exhibit Hall

10:55  Oxidative Stress and Pathogenesis of COPD: Emerging Therapeutic Targets
Irfan Rahman, Ph.D., Associate Professor, Department of Environmental Medicine, University of Rochester Medical Center

11:25  PANEL DISCUSSION: Emerging Therapies for COPD: Clinical Needs, Commercial Potential, Research and Development Challenges
Moderator: Tim Joslin, Managing Director, Europe, Defined Health
Panelists:
- John Efthimiou BSc MD FRCP, Chief Development and Medical Officer, ProtAffin Biotechnologie AG
- Stephen G. Farmer, Ph.D., Global Product Strategy Director, Respiratory Business Franchise, Novartis Pharma AG

12:25 pm  Sponsored Presentation (Opportunity Available)

12:40  Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on your own

PRE-CLINICAL AND CLINICAL UPDATE ON TARGETS FOR COPD

1:55  Chairperson’s Remarks

2:00  Clinical Results in COPD: Use of ACE Inhibitors
David W. Moskowitz, M.D., Chairman, CEO and Chief Medical Officer, GenoMed, Inc.

2:30  Targeting a Novel Pathway of Pulmonary Inflammation in COPD: Proteases, Products, and Therapeutics
Amit Gaggar, M.D., Ph.D., Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham

3:00  Networking Ice Cream Refreshment Break in the Exhibit Hall

3:40  Title to be Announced
Paul Newbold PhD., Senior Director Clinical Science, Clinical Development Respiratory, MedImmune

4:10  Development of an Oral Vaccine for Treating COPD

4:40  PANEL DISCUSSION: Use of New Models and Biomarkers for Understanding COPD

5:10  Close of Conference

---

Suggested Event Package
(11/1-4)
Pre-Conference Short Courses

November 1

Conference

November 2-3

Ion Channels as Therapeutic Targets

November 3-4

New Ways to Tackle COPD and Other Chronic Pulmonary Diseases

---

DiscoveryOnTarget.com

Email: reg@healthtech.com  Phone: 781-972-5400  Fax: 781-972-5425
PAYMENT INFORMATION

Single Conference Package   academic, Government, November 1 - November 3
November 2-3 November 3-4
Registrations after September 17, 2010 and on-site registered Conference Delegates Save $100

GROUP DISCOUNTS AVAILABLE!

- Special rates are available for multiple attendees from the same organization.
- For more information on group discounts contact David Cunningham at 781-972-5472.
- I cannot attend but would like to purchase the Discovery On Target conference CD for $750 (plus shipping).
- Massachusetts delivery will include 6.25% sales tax.
- Please send this form with your check or credit card information listed below.

How would you prefer to receive notices from CHI? Email: ☐ Yes ☐ No Fax: ☐ Yes ☐ No
Email ___________________________ Fax ___________________________

*Email is not a mandatory field. However, by excluding your email you will not receive notification about online access to pre-conference presenter materials, conference updates, networking opportunities and requested eNewsletters.

SHORT COURSE PRICING

Add a Short Course to your Conference Registration and Save $100

Commercial Academic, Government, Hospital-affiliated
Single Short Course $695 $395
Two Short Courses $995 $595
Three Short Courses $1295 $795
Registered Conference Delegates Save $100

REQUIRED: Please select the short course(s) you will be attending

November 1
- SC1 AllostERIC Modulators of GPCRs
- SC2 Structure-Based Design of Ion Channel-Linked Receptors

November 3
- SC5 Best Practices for Setting Up Effective RNAi Screens
- SC6 In Vivo Discovery and Validation Using RNAi
- SC7 Assessing Cardio Safety of Diabetes Drug Candidates

CONFERENCE PRICING

SINGLE CONFERENCE PACKAGE
Includes access to one (1) conference (excluding short courses)
Advance Registration Deadline until September 17, 2010
- Commercial $1,445 $775
- Registrations after September 17, 2010 and on-site $1,645 $875

REQUIRED: Please select the 1 conference you will attend

November 2-3 November 3-4
- Track 1: HDAC Inhibitors or Track 6: Kinase Inhibitors
- Track 2: GPCR-Based Drug Discovery or Track 7: Diabetes Drug Discovery
- Track 3: Ion Channels or Track 4: PI3K Pathways
- Track 5: RNAi for Functional Screening or Track 8: COPD

MULTI CONFERENCE PACKAGE
Includes access to two (2) conferences (excluding short courses)
Advance Registration Deadline until September 17, 2010
- Commercial $2,345 $1,025
- Registrations after September 17, 2010 and on-site $2,495 $1,095

REQUIRED: Please select the 2 conferences you’re most likely to attend

November 2-3 November 3-4
- Track 1: HDAC Inhibitors or Track 6: Kinase Inhibitors
- Track 2: GPCR-Based Drug Discovery and Track 7: Diabetes Drug Discovery
- Track 3: Ion Channels or Track 4: PI3K Pathways
- Track 5: RNAi for Functional Screening or Track 8: COPD

POSTER DISCOUNT
- Commercial $50 off
- Academic, Government, Hospital-affiliated $50 off

Present a Poster and Save $50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved, and your registration paid in full by September 22, 2010. Register online, or by phone, fax or mail. Indicate on the registration form that you would like to present a poster and you will receive abstract submission instructions via email.

NAME ____________________________________________
Company ____________________________________________
Address ____________________________________________
City/State/Postal Code ________________________________
Country ____________________________________________

HOW TO REGISTER:
Online: www.DiscoveryOnTarget.com

Key Code DOT F

www.barnettinternational.com

CHI Insight Pharma Reports
A series of diverse reports designed to keep life science professionals informed of the latest trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets.
For more information, visit: www.barnettinternational.com.

Barnett Educational Services
Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit: BarnettEducationalServices.com.

Additional Registration Details
Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Group Discounts
Special rates are available for multiple attendees from the same organization.
Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.

Handicapped Equal Access
In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

Substitution/Cancellation Policy
In the event that you need to cancel a registration, you may:
- Transfer your registration to a colleague within your organization.
- Credit your registration to another Cambridge Healthtech Institute program.
- Request a refund minus the cost ($750) of ordering a copy of the CD.

NOTE: Cancellations will only be accepted up to two weeks prior to the conference.

Program and speakers are subject to change.

Video and audio recording of any kind is prohibited onsite at all CHI events.

www.chimediagroup.com